Despite officials’ warnings and pleas, travel over Thanksgiving is expected to hit a pandemic peak.

The nation’s health experts on Sunday pleaded with Americans to stay home over the Thanksgiving holiday and forgo any plans to travel or celebrate at large family gatherings, even as airports have recorded a significant rise in passengers.

Dr. Anthony S. Fauci, the country’s top infectious disease specialist, and other health experts relayed a clear message on Sunday morning news shows: with coronavirus cases surging to record levels across the country, turning nearly every state into a hot zone of transmission, the risk of getting infected, whether in transit or in even small indoor gatherings, is high.

Up to 50 million people could be traveling on roads and through airports in the United States over Thanksgiving this year, according to AAA, the biggest travel surge since the pandemic began, despite strong cautions from the Centers for Disease Control and Prevention and other health authorities. A video of a packed airport in Phoenix has been circulating widely on social media. As of Sunday, 47 states — all but Hawaii, Maine and Vermont — were considered high-risk zones for viral transmission, and nationwide hospitalizations were at a record 83,227.

“Please seriously consider decisions that you make,” Dr. Fauci said on the CBS show “Face the Nation.” Encountering large numbers of people in airports and on planes is particularly dangerous, he said. Although airlines have invested in air circulation and ventilation systems to minimize viral transmission, Dr. Fauci said, “sometimes when you get a crowded plane, or you’re in a crowded airport, you’re lining up, not everybody’s wearing masks — that puts yourself at risk.”

And gathering indoors, whether you travel or not, carries risk. “When you’re eating and drinking, obviously, you have to take your mask off,” Dr. Fauci said. “We know now that those are the kinds of situations that are leading to outbreaks.”

Dr. Tom Inglesby, director of the Center for Health Security of the Johns Hopkins Bloomberg School of Public Health, said on Fox News on Sunday that because about half of infections are spread by people who don’t have any symptoms, “you can’t assume that you don’t have the virus, and you can’t assume that the people whose home you’re about to enter don’t have the virus, at this point in our pandemic.”

He recommended celebrating Thanksgiving only with the people you live with. People who choose to visit others’ homes should spend as much time as possible outdoors and “should be wearing masks indoors when they’re together, and only removing them when they’re eating.”

In Tulsa, Okla., Victory, a megachurch, canceled a “Friendsgiving” service on Sunday that had called on members to bring a friend after it prompted an outcry, instead opting to give away boxed meals, NBC News reported. The church did not respond to a request for comment regarding its planned “Thanksgiving Day Brunch,” which, according to its website, is set to be held on Thursday in the church’s cafeteria.

Dr. Fauci and others warned that Americans’ behavior over Thanksgiving would have critical implications for

Read more

The Health 202: Obamacare marketplaces survived Trump’s term better than expected

“The overall impact of the Trump administration’s policies towards the marketplaces have probably been more muted than most expected — at least so far,” said Adam Gaffney, a professor at Harvard Medical School and president of Physicians for a National Health Program.

Enrollment in Healthcare.gov and the state-based marketplaces is open through Dec. 15.

People can shop for private plans, and qualify for federal subsidies if their income is between 133 percent and 400 percent of the federal poverty level.

To the concern of health-care advocates, enrollment has ticked down over the past four years, contributing to the nation’s worsening uninsured rate amid the coronavirus pandemic and fueling a growing sense among Democrats that further health restructuring is needed.

Yet by some measures, the marketplaces look healthier than ever.

Individual insurance premiums and choices have steadily improved over the past four years, despite Democrats’ insistence that the administration’s policies would destroy the marketplaces. That trend will continue in the 2021 enrollment season.

“One thing the marketplaces proved is how resilient they actually are,” said Andy Slavitt, former administrator of the Centers for Medicare and Medicaid Services under President Barack Obama.

Still, there’s a clear difference in how a Joe Biden administration would approach the ACA.

It certainly would invest more in boosting marketplace enrollment, advisers say. The Democratic nominee, if he wins tomorrow’s election, is expected to restore funds Trump scrapped to advertise the law and may push Congress to pass legislation increasing the income-based subsidies available to people. 

A Democrat-led administration may also reverse some of the changes President Trump made to the marketplaces — although Trump’s record on them is more nuanced than either party claims.

“The truth is somewhere in middle between what Republicans say and what Democrats say,” said Larry Levitt, a vice president for the Kaiser Family Foundation.

The average Obamacare customer can choose from plans offered by four to five issuers.

That’s up from an average of three to four issuers in 2020, according to data from the Centers for Medicare and Medicaid Services. Four percent of enrollees will have access to plans from just one issuer, up from 12 percent of enrollees this year.

And premiums are declining for the third straight year. The average premiums for the second-lowest-cost “silver”-level plan will be 2 percent lower next year. Average premiums for these “benchmark” plans have declined 8 percent since 2018.

“Despite the uncertainty of the pandemic and concerns about the future of the ACA, the marketplaces are strong and healthy, and premiums for high-quality, comprehensive coverage remain very affordable,” said Joshua Peck, co-founder of Get America Covered — a nonpartisan group that has worked to spread the word about the marketplaces even as the administration has cut advertising for it.

It’s a distinct shift from how things looked during the Obama administration. The first few years of the marketplaces were marked by double-digit premium increases and a steady stream of exits by insurers, as they struggled with how to price and sell insurance

Read more

The Asia Pacific liposome drug delivery market is expected to reach US$ 1,562.92 million in 2027 from US$ 759.81 in 2019

The market is estimated to grow with a CAGR of 9. 6% from 2020-2027. The growth of the market is attributed to the some key driving factors such as high incidence of chronic diseases amongst the population, an upsurge in need for non-invasive drug delivery solutions, increasing investments in R&D for pharmaceutical companies.

New York, Oct. 29, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Asia Pacific Liposome Drug Delivery Market Forecast to 2027 – COVID-19 Impact and Regional Analysis By Product ; Technology ; Application, and Country” – https://www.reportlinker.com/p05978829/?utm_source=GNW
However, high expense involved in the development of drug delivery systems is expected to obstruct the growth of the market to a certain extent during the forecast years.

Liposomes are small sphere-shaped artificial vesicles synthesized from cholesterol and phospholipids. They have multiple layers and a diameter range of 0.01 to 5.0 um. They also have hydrophilic and hydrophobic properties which help liposomes to encapsulate hydrophobic and hydrophilic drugs to be delivered to targeted body site. Liposomes provide an assured system for targeted drug delivery and thereby is the factor influencing the Liposome Drug Delivery market size growth. Liposomes are widely used for enclosing all types of drug molecules such as acyclovir, chloroquine diphosphate, paclitaxel, tropicamide, and cyclosporine. Liposomes are used as a drug carrier for drug therapy for many diseases since they are biodegradable and biocompatible. Also, they have many therapeutic properties like anticancer drugs, genetic materials, proteins, vaccines, macromolecules, and thus can be encapsulated in liposomes.

Research and development (R&D) in liposomal drug delivery systems are increasing across the world due to the increasing prevalence of chronic disease.Drug delivery is the process of dispensing a pharmaceutical compound to attain a therapeutic effect in humans.

Liposomal drug delivery offers multiple advantages such as better pharmacokinetics and pharmacodynamics, enhanced therapeutic efficacy, and decreased toxicity making these delivery systems ideal for patients suffering from various chronic conditions.

Death among the population worldwide has increased due to cancer.The targeted drug delivery system delivers the drug in a controlled manner at a preselected bio site.

Nanotechnology-based delivery systems are making a crucial impact on cancer treatment, and the polymers play a key role in the development of Nano particulate carriers for cancer therapy.Some of the major technological advantages involved in the nanotherapeutic drug delivery systems (NDDS) are prolonged half-life, improved bio-distribution, increased circulation time of the drug, controlled and sustained release of the drug, versatility of route of administration, increased intercellular concentration of the drug, and many more.

The liposomal carriers used in nanotechnology drug delivery systems are likely to experience rapid adoption, which in turn is propelling the market growth.

As per the data provided by, European Society for Medical Oncology, China estimated there were 4.3 million new cancer cases and more than 2.8 million cancer deaths in China in 2015, with lung cancer the most common cancer and the leading cause of cancer death. With high incidences and mortality, cancer is the leading cause of death in China and

Read more

The Asia Pacific pulmonary devices market is expected to reach US$ 8,196.82 million by 2027 from US$ 3,661.53 million in 2019

The market is estimated to grow at a CAGR of 10. 6 % during 2019–2027. The growth of the pulmonary devices market in Asia Pacific is attributed to the increasing prevalence of respiratory diseases and growing number of COVID-19 cases.

New York, Oct. 29, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Asia Pacific Pulmonary Devices Market Forecast to 2027 – COVID-19 Impact and Regional Analysis By Type ; Application ; and End User and country” – https://www.reportlinker.com/p05978832/?utm_source=GNW
Factors such as unfavorable reimbursement scenario associated with the pulmonary device are likely to restrain the growth of the market.

Additionally, strategic activities by manufacturers and increasing preference of home care products are likely to fuel the growth of the pulmonary devices market during the forecast period.

Pulmonary or respiratory devices are used to remove mucus and secretions from the respiratory tract. These medical devices are focused on diagnosis, control, treatment, management, and evaluation of the problems associated with respiratory tract.

The higher prevalence of respiratory disorder is mainly due to the decrease in size of the upper airway lumen in aging population.Millions of people suffer from various respiratory diseases; lung diseases are the most common medical conditions.

Smoking, genetic factors, and infections are among the common factors responsible for respiratory diseases. Medical conditions such as asthma and chronic obstructive pulmonary disease (COPD), chronic bronchitis, cystic fibrosis, and lung cancer are among the significant public health burdens.

According to a new Tulane University study published in The Lancet, chronic obstructive pulmonary disease (COPD) is widespread in China with 8.6% of the country’s adult population, i.e. almost 100 million people suffering from the chronic lung disease. Additionally, among India’s 1.31 billion people, about 6% of children and 2% of adults have asthma.

The patients suffering with these respiratory disorders commonly experience difficulty in breathing.Thus, the availability of various pulmonary devices has helped improve the survival rates of the patients suffering from abovementioned medical conditions.

The rising demand for various therapeutic devices among patients with respiratory disorders is expected to augment the growth of the market during the forecast period.

Asia Pacific countries are expected to witness massive challenges due to increasing COVID-19 cases.To manage the COVID-19 outbreak and provide efficient treatment to patients in the region, local medical device companies are ramping up the production of alternative respiratory systems in the Asian countries.

The governments in India and Australia, among others are taking initiative to fulfill the demand of oxygen during COVID-19 pandemic. Thus, the development of these solutions is likely to create a positive impact on market growth in the Asian region.

In 2019, the therapeutic devices segment held the largest share in the market and is expected to retain its dominance till 2027.The multi-modal and multi-functional use of therapeutic devices for a wide range of pulmonary diseases is expected to account for the growth of the therapeutic devices segment over the coming years.

On the other hand, the consumables and accessories segment is expected to witness fastest growth

Read more

The Amniotic membrane market is expected to reach US$ 1175.2million in 2027 from US$ 667.4million in 2019

The market is estimated to grow with a CAGR of 7. 5% from 2020-2027. The growth of the market is attributed to some key driving factors such as high implementation of amniotic membranes in medical science and new developments and increased investments of amniotic membranes.

New York, Oct. 28, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “North America Amniotic Membrane Market Forecast to 2027 – COVID-19 Impact and Regional Analysis By Enzyme ; Application ; End User, Country” – https://www.reportlinker.com/p05978887/?utm_source=GNW
However, limitations encountered while using amniotic membranes in emerging nations are expected to obstruct the growth of the market to a certain extent during the forecast years.

The amniotic membrane is the innermost fetal layer, lining the amniotic cavity and protecting the fetus during pregnancy.The outer layer, termed chorionic membrane, further separates the fetus from maternal tissues.

Various researches focusing on the physiological functions of fetal layers have shown that amniotic membrane not only provides physical support for the fetus but also serves as a metabolically active filter through direct interaction with amniotic fluid. The translucent, avascular, low immunogenic, anti-inflammatory, anti-scarring, and wound healing properties of amniotic membrane allow this material function beyond its role in vivo and assume a wide range of applications in regenerative medicine.

The clinical use of amniotic membrane has a long history, with the first reports on its application in the treatment of skin burns and wounds more than a century ago.These ground-breaking studies played a significant role in advancing the use of an amniotic membrane in surgery, especially in areas such as the reconstruction of the corneal and conjunctival surfaces, treatment of open ulcers and traumatic wounds, and skin transplantation.

In parallel, the shelf life of the amniotic membrane has been extended by irradiation, air-drying, lyophilization, cryo-preservation, and glycerol preservation techniques. These methods are expected to further expand the use of an amniotic membrane in ophthalmology to treat corneal, conjunctival and limbal lesions, burns, scars and defects as well as general surgery to reconstruct the skin, genitourinary tract and other surfaces.

Amniotic membranes also appear to have natural protective and reparative functions; they may also be used for efficient delivery of specific factors to enhance the protection or repair of damaged tissue through genetic modification.

Based on enzyme, the amniotic membrane market, by enzyme, is segmented into cryopreserved amniotic membrane, and dehydrated amniotic membrane. The cryopreserved amniotic membrane segment held the largest share of the market in 2019, whereas the dehydrated amniotic membrane segment is anticipated to register the highest CAGR in the market during the forecast period.

Based on application, the amniotic membrane market, by application, is segmented into surgical wounds, ophthalmology, and others. The surgical wounds segment held the largest share of the market in 2019, also the segment is anticipated to register the highest CAGR in the market during the forecast period…
Based on end-user, the amniotic membrane market is segmented into hospitals, ambulatory surgical centers, specialty clinics, research institute and academic institutes.The hospitals segment held the

Read more

Fauci says findings on a potential coronavirus vaccine are expected by early December

Dr. Anthony Fauci

“We will know whether a vaccine is safe and effective by the end of November, beginning of December,” the director of the US National Institute of Allergy and Infectious Diseases said. “The amount of doses that will be available in December will not certainly be enough to vaccinate everybody — you’ll have to wait several months into 2021.”

Speaking to the BBC’s Andrew Marr Show, Fauci added that the vaccination of a “substantial proportion of the population” so there could be a “significant impact on the dynamics of the outbreak” may not be possible until the second or third quarter of 2021.

Pence adviser Marty Obst tests positive for coronavirus

“What I do foresee is that with a successful vaccine and the continuation of some form of public health measures, as we go and progress through the months of 2021, getting towards the third and fourth quarter, we will see a considerable approach towards some form of normality,” Fauci told Marr.

Pressed on whether he believes US President Donald Trump is correct in saying that the United States is “rounding the corner” in the course of the pandemic, Fauci said he believes this is untrue.

“The data speak for themselves,” Fauci said.

“Unfortunately, I am sorry to see what I’m viewing from a distance, what I’m seeing in the UK … after getting hit pretty badly the way we did, you went down to a pretty low level, but now you’re starting to escalate in the same manner that we are here,” he added.

Source Article

Read more

Traditional Chinese Medicine Market Expected to Witness A CAGR Of More than 5% Over the Forecast Period 2020-2030 – Persistence Market Research

NEW YORK, Oct. 23, 2020 /PRNewswire/ — Traditional Chinese medicine is one of the oldest systems of health and wellness that has been used in China for thousands of years. Other medicines mainly focus on treating a disease. But traditional Chinese medicines aim to increase immune power and look at the entire well-being. The most common type of traditional Chinese medicines includes herbal products, acupuncture, and Tai Chi, among others.

According to a latest report published by PMR, the global traditional Chinese medicine marketis expected to witness a CAGR of more than 5% over the forecast period (2020–2030).

Key Takeaways from Traditional Chinese Medicine Market Study  

  • Non-traditional Chinese medicines is the leading segment by product in the global traditional Chinese medicine market. The Autism Spectrum disorder (ASD) segment has been gaining more traction in recent years, and is expected to expand at a rate of 6.7% during the forecast period.
  • North America is the leading region in the traditional Chinese medicine market, followed by Europe.
  • East and South Asia, including China, South Korea, Japan, India, and ASEAN countries, is the fastest-growing region in the traditional Chinese medicine market, due improving medical infrastructure.
  • Tong Ren Tang, Pfizer, and Novartis AG are amongst the leading players in the global traditional Chinese medicine market. These companies invest most of their revenue in R&D, and focus on strengthening their distribution channels to maintain a leading position in the traditional Chinese medicine market space.
  • 100+ health systems are partnering with retail chains, providing physician oversights and increased patient traffic to retail clinics, and extending health system networks to new patient populations.
  • The COVID-19 pandemic is a cause for concern, which has deprioritized non-essential medical treatments. This will hurt the growth of the global traditional Chinese medicine market in the short term

Get PDF Brochure for Research Insights at: https://www.persistencemarketresearch.com/samples/16219

“Increasing incidence of ADHD to boost growth of global traditional Chinese medicine market,” says a PMR analyst.

Rising prevalence of ADHD is a major factor contributing to revenue growth of the traditional Chinese medicine market across the globe. The exact cause of ADHD is still unclear, although genetic influence is observed in most cases.

As per data released by the Centers for Disease Control and Prevention (CDC), approximately 6.1 million (9.4%) – 388,000 children aged 2–5 years, 4 million children aged 6–11 years, and 3 million children aged 12–17 years – were diagnosed with ADHD in the U.S. In Spain, pooled prevalence of ADHD in a population of 361,580 representing children and adolescents was estimated at 6.8% from the last decade.

Get Customization on this Report: https://www.persistencemarketresearch.com/request-customization/16219 

Prevalence of ADHD is rising at an alarming rate, which is expected to fuel revenue growth of ADHD therapeutics such traditional Chinese medicines, as there is no specific treatment for this disorder

Product Innovation – Key Strategy of Traditional Chinese Medicine Market Players

Major players in the global traditional Chinese medicine market are introducing innovative products

Read more

Traditional Chinese Medicine Market Expected to Witness A CAGR Of More than 5% Over the Forecast Period 2020-2030

NEW YORK, Oct. 23, 2020 /PRNewswire/ — Traditional Chinese medicine is one of the oldest systems of health and wellness that has been used in China for thousands of years. Other medicines mainly focus on treating a disease. But traditional Chinese medicines aim to increase immune power and look at the entire well-being. The most common type of traditional Chinese medicines includes herbal products, acupuncture, and Tai Chi, among others.

Persistence_Market_Research

According to a latest report published by PMR, the global traditional Chinese medicine market
is expected to witness a CAGR of more than 5% over the forecast period (2020-2030).

Key Takeaways from Traditional Chinese Medicine Market Study

  • Non-traditional Chinese medicines is the leading segment by product in the global traditional Chinese medicine market. The Autism Spectrum disorder (ASD) segment has been gaining more traction in recent years, and is expected to expand at a rate of 6.7% during the forecast period.
  • North America is the leading region in the traditional Chinese medicine market, followed by Europe.
  • East and South Asia, including China, South Korea, Japan, India, and ASEAN countries, is the fastest-growing region in the traditional Chinese medicine market, due improving medical infrastructure.
  • Tong Ren Tang, Pfizer, and Novartis AG are amongst the leading players in the global traditional Chinese medicine market. These companies invest most of their revenue in R&D, and focus on strengthening their distribution channels to maintain a leading position in the traditional Chinese medicine market space.
  • 100+ health systems are partnering with retail chains, providing physician oversights and increased patient traffic to retail clinics, and extending health system networks to new patient populations.
  • The COVID-19 pandemic is a cause for concern, which has deprioritized non-essential medical treatments. This will hurt the growth of the global traditional Chinese medicine market in the short term

Get PDF Brochure for Research Insights at: https://www.persistencemarketresearch.com/samples/16219

“Increasing incidence of ADHD to boost growth of global traditional Chinese medicine market,” says a PMR analyst.

Rising prevalence of ADHD is a major factor contributing to revenue growth of the traditional Chinese medicine market across the globe. The exact cause of ADHD is still unclear, although genetic influence is observed in most cases.

As per data released by the Centers for Disease Control and Prevention (CDC), approximately 6.1 million (9.4%) – 388,000 children aged 2-5 years, 4 million children aged 6-11 years, and 3 million children aged 12-17 years – were diagnosed with ADHD in the U.S. In Spain, pooled prevalence of ADHD in a population of 361,580 representing children and adolescents was estimated at 6.8% from the last decade.

Get Customization on this Report: https://www.persistencemarketresearch.com/request-customization/16219

Prevalence of ADHD is rising at an alarming rate, which is expected to fuel revenue growth of ADHD therapeutics such traditional Chinese medicines, as there is no specific treatment for this disorder

Product Innovation – Key Strategy of Traditional Chinese Medicine Market Players

Major players in the global traditional Chinese medicine market are introducing innovative products to retain

Read more

The global constipation treatment market is expected to reach US$ 13,386.19 million in 2027 from US$ 8,533.89 million in 2019

The market is estimated to grow with a CAGR of 5. 9% from 2020-2027. The increasing number of FDA approvals and drug development activities are likely to accelerate the market’s growth during the forecast period.

New York, Oct. 21, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Constipation Treatment Market Forecast to 2027 – COVID-19 Impact and Global Analysis by Therapeutic ; Disease ; Distribution Channel, and Geography” – https://www.reportlinker.com/p05978062/?utm_source=GNW
The majority of the established and new players are coming forward to manufacture drugs for the disease, which will lead to the high availability of the drugs in the market.

This availability of drugs is expected to boost consumption, and hence the constipation treatment market. For instance, in 2019, Ardelyx, Inc. got FDA approval for its Ibsrela (tenapanor) for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. The newly approved drug is a minimally-absorbed small molecule that acts locally in the gastrointestinal (GI) tract to decrease the abdominal pain and increase the bowel movements in IBS-C patients. Similarly, in January 2018, Synergy Pharmaceuticals Inc. received FDA’s approval for TRULANCE (plecanatide) 3 mg tablet/ per day to treat irritable bowel syndrome with constipation (IBS-C) in adults. TRULANCE was already approved as a medicine for treating chronic idiopathic constipation (CIC) in adults.

The constipation treatment market is projected to witness the introduction of generic drugs, which will eventually positively impact the growth of the market.For instance, in 2020, Teva Pharmaceutical, and Israel based drug manufacturing company, received FDA approval for its first generic version irritable bowel syndrome drug Linzess (linaclotide).

Additionally, according to company estimates, the drug is anticipated to observe thriving sales in the market. Likewise, in November 2018, EA Pharma Co., Ltd. in Japan has launched its MOVICOL in powdered form. The product is the first polyethylene glycol preparation prescribed to treat chronic constipation in adults and children age two years and above. Thus, due to the number of product launches in the market, the constipation treatment market will flourish during the forecast period.
Based on therapeutic, the constipation treatment market is segmented into laxatives, chloride channel activators, peripherally acting mu-opioid receptor antagonists, GC-C agonists, and 5-HT4 receptor agonists.The laxatives segment held the largest share of the market in 2019.

However, GC-C agonists segment is anticipated to register the highest CAGR in the market during the forecast period.
Based on disease, the constipation treatment market is segmented into chronic idiopathic constipation, irritable bowel syndrome with constipation, and opioid-induced constipation. The chronic idiopathic constipation segment held the largest share of the market in 2019, and is estimated to register the highest CAGR in the market during the forecast period.
Based on distribution channel, the constipation treatment market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment held the largest share of the market in 2019, and is estimated to register the highest CAGR of 6.4% in the market during the forecast period.
The Food and Drug Administration (FDA), Canadian Association

Read more

The global hospital gowns market is expected to reach US$ 4,542.67 million by 2027 from US$ 2,620.88 million in 2019

The market is estimated to grow with a CAGR of 7. 2% from 2020 to 2027. The growth of the market is attributed to key driving factors, such as increase in number surgical of procedures, initiatives to support health protection of patients from hospital-acquired infections, and key players for hospital gowns focused toward introducing new products.

New York, Oct. 21, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Hospital Gowns Market Forecast to 2027 – COVID-19 Impact and Global Analysis by Type, Risk Type, and Usability, and Geography” – https://www.reportlinker.com/p05978081/?utm_source=GNW
However, adoption of robotic surgeries is expected to obstruct the growth of the market to a certain extent during the forecast period.

There is a rise in number of cardiovascular surgeries and general surgeries performed across the globe.In Europe, the conditions and symptoms such as rise in diabetic cases and lifestyle changes are leading to an increase in number of cardiovascular surgeries and general surgeries.

The incidence of cardiovascular diseases has increased in European countries since the last 25 years.As per the European Cardiovascular Disease Statics, in 2015, about 85 million people in Europe and 49 million in the EU were suffering from cardiovascular diseases.

Along with cardiovascular surgeries, number of general surgeries is also increasing which is expected to fuel the growth of the hospital gowns market during the forecast period.

From the perspective of chronic conditions, cancer and diabetes are the leading causes of mortality across the globe.For instance, as per a study conducted by the American Cancer Society (ACS), in 2018, approximately 1,735,350 new cancer cases were diagnosed in the US.

Furthermore, according to the International Diabetes Federation (IDF), in 2017, an estimated 46 million Americans were suffering from diabetes.This number is expected to reach 62 million by 2045.

The same study also mentioned that ~425 million people worldwide were living with diabetes in 2017 and the number is likely to reach ~629 million by 2045.

Based on type, the hospital gowns market is segmented into surgical gowns, non-surgical gowns, and patient gowns.The surgical gowns segment held the largest share of the market in 2019, and it is anticipated to register the highest CAGR in the market during the forecast period.

Growth of this segment is attributed to rising number of surgeries across the globe, increasing prevalence of chronic diseases, and growing focus on prevention of hospital-acquiredinfections. In addition, continuous innovations by surgical gown manufacturers is further accelerating the growth of the market.
The hospital gowns are among the highly used hospital consumables.Hospitals utilize a large quantity of hospital gowns for the general patients.

Moreover, due to the COVID-19 pandemic, there has been a tremendous rise in the demand for hospital gowns worldwide.Various market players of non-healthcare businesses are engaged in the production of hospital gowns to fulfill the high demand.

The existing players are ramping up the production and supply chain for the hospital gowns.The disposable hospital gowns have become one of the crucial components in the personal protective equipment (PPE) kit that

Read more